PACAP can bind to three different receptors; however, because PAC1 is the receptor most commonly associated with migraine-related effects (25, 26), we tested the PAC1 inhibitor M65 in our chronic migraine and OIH models. Here, ADCYAP1 is linked to migraine disorder.